Immutep Limited (PRRUF)

Overview

Immutep Limited is a pioneering clinical-stage biotechnology firm dedicated to the innovation of LAG-3 based Immunotherapy treatments aimed at combating cancer and autoimmune diseases. The company's foundation is built upon the development and commercialization of groundbreaking therapies that target Lymphocyte Activation Gene-3 (LAG-3), a critical cell surface molecule integral to the regulation of the immune system. By leveraging the inherent power of patients' immune systems through their novel LAG-3 immunotherapies, Immutep aims to provide effective treatments for those suffering from cancer and autoimmune conditions. Initially established in 1987 and formerly known as Prima BioMed Ltd, the company underwent a rebranding to Immutep Limited in November 2017 and is headquartered in Sydney, Australia.

Products and Services

• Eftilagimod Alpha (Efti or IMP321)

Immutep's flagship product, eftilagimod alpha, currently in clinical trials, is poised to revolutionize the treatment of various cancers. This therapeutic candidate utilizes a multi-pronged approach to bolster the immune system's ability to combat cancer cells, and is being evaluated across several clinical trials including TACTI-002 (Phase II for head and neck squamous cell carcinoma [HNSCC] and non-small cell lung cancer [NSCLC]), TACTI-003 (Phase IIb for treating HNSCC), INSIGHT-003 (Phase I for NSCLC treatment), and INSIGHT-005 (Phase I/IIa for treating solid tumors).

• IMP761

An innovative immune system modulator, IMP761 is being developed as an agonist of lymphocyte activation gene 3 (LAG-3) for the treatment of autoimmune diseases. This therapeutic approach aims at targeting the underlying immune response mechanisms responsible for autoimmune conditions.

• IMP701

As an antagonist antibody, IMP701 plays a critical role in stimulating T cell proliferation, which is a cornerstone for cancer treatment initiatives. By enhancing the body's immune response to cancer cells, IMP701 represents a promising avenue for cancer immunotherapy.

• IMP731

Focused on alleviating autoimmune ailments, IMP731 functions as a depleting antibody that specifically targets and removes autoreactive T cells. This targeted approach aims to diminish the immunological reactions responsible for autoimmunity, highlighting the company's dedication to addressing a broad spectrum of immune-related conditions.

In addition to its robust product pipeline, Immutep has forged strategic collaboration agreements with industry giants such as GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., the Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. These partnerships are instrumental in advancing the development and commercialization of Immutep's innovative LAG-3 immunotherapy treatments.